IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release.
We investigated the effects of IgE versus IL-4 on Fc epsilon RI surface expression in differentiated human mast cells derived in vitro from umbilical cord blood mononuclear cells. We found that IgE (at 5 micrograms/ml) much more strikingly enhanced surface expression of Fc epsilon RI than did IL-4 (at 0.1-100 ng/ml); similar results were also obtained with differentiated mouse mast cells. However, IL-4 acted synergistically with IgE to enhance Fc epsilon RI expression in these umbilical cord blood-derived human mast cells, as well as in mouse peritoneal mast cells derived from IL-4-/- or IL-4+/+ mice. We also found that: 1) IgE-dependent enhancement of Fc epsilon RI expression was associated with a significantly enhanced ability of these human mast cells to secrete histamine, PGD2, and leukotriene C4 upon subsequent passive sensitization with IgE and challenge with anti-IgE; 2) preincubation with IL-4 enhanced IgE-dependent mediator secretion in these cells even in the absence of significant effects on Fc epsilon RI surface expression; 3) when used together with IgE, IL-4 enhanced IgE-dependent mediator secretion in human mast cells to levels greater than those observed in cells that had been preincubated with IgE alone; and 4) batches of human mast cells generated in vitro from umbilical cord blood cells derived from different donors exhibited differences in the magnitude and pattern of histamine and lipid mediator release in response to anti-IgE challenge, both under baseline conditions and after preincubation with IgE and/or IL-4.
Yamaguchi
M
M
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Sayama
K
K
Yano
K
K
Lantz
C S
CS
Noben-Trauth
N
N
Ra
C
C
Costa
J J
JJ
Galli
S J
SJ
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000502:physiology; D002454:Cell Differentiation / Q000276:immunology; D002462:Cell Membrane / Q000276:immunology / Q000378:metabolism; D004338:Drug Combinations; D004357:Drug Synergism; D005312:Fetal Blood / Q000166:cytology / Q000276:immunology / Q000378:metabolism*; D006636:Histamine Release / Q000276:immunology*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology / Q000502:physiology*; D007074:Immunoglobulin G / Q000502:physiology; D015847:Interleukin-4 / Q000502:physiology*; D050356:Lipid Metabolism; D008055:Lipids / Q000276:immunology; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D017455:Receptors, IgE / Q000096:biosynthesis* / Q000378:metabolism; D014471:Umbilical Veins; D015854:Up-Regulation / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D004338:Drug Combinations; D007074:Immunoglobulin G; D008055:Lipids; D017455:Receptors, IgE; C026408:anti-IgE antibodies; D015847:Interleukin-4; D007073:Immunoglobulin E